Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (17,122,327)	$ (12,310,287)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	2,372,783	1,770,950
Depreciation and amortization	166,174	5,980
Changes in operating assets and liabilities:
Receivable due from collaboration agreement	(184,272)	(489,221)
Research and development tax incentive receivable	(78,257)	(958,363)
Prepaid assets and other assets	939,995	285,090
Accounts payable	1,856,851	213,399
Accrued compensation	(416,910)
Deferred revenue	218,000	685
Operating lease obligation	(12,783)
Net cash used in operating activities	(12,260,746)	(11,481,767)
Cash flows from investing activities:
Purchases of property and equipment	(632,684)	(600,210)
Net cash used in investing activities	(632,684)	(600,210)
Cash flows from financing activities:
Net proceeds from issuance of common stock		28,015,019
Payment of offering costs in connection with ATM	(26,180)
Proceeds from issuance of common stock for stock option exercises	10,185	689,753
Proceeds from issuance of common stock for warrant exercises		180,212
Net cash (used in) provided by financing activities	(15,995)	28,884,984
Effect of exchange rate changes on cash and cash equivalents	5,006	(36,473)
Net change in cash and cash equivalents	(12,904,419)	16,766,534
Cash and cash equivalents at beginning of period	33,794,672	35,300,805
Cash and cash equivalents at end of period	20,890,253	52,067,339
Supplemental disclosure of non-cash investing and financing activities:
Accrued offering costs	133,209
Cashless exercise of warrants		$ 416
ROU asset obtained under for new operating lease	$ 238,021